source
- Pfizer halts phase 2 trial of CXCR5 antibody for immune thrombocytopeniaPfizer announced it is ending a phase 2 study of its CXCR5-targeting antibody PF-06835375 in patients with primary immune thrombocytopenia (ITP). The decision was described as a business decision a…
- Reporter urges audiences to skip new Elizabeth Holmes documentaryMatthew Herper, a reporter covering medical innovation, recounts his two interviews with Elizabeth Holmes in 2015, at the peak of Theranos hype. The first interview occurred just before John Carre…